Sandoz Updates Financial Guidance Amid Supply Constraints
The company adjusted its 2026 sales growth expectations while raising its target for core earnings margins.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Do you trust pharmaceutical companies to handle supply constraints without compromising long-term financial stability?
Sandoz has lowered its full-year sales growth guidance as biosimilar supply constraints and difficult market conditions in Germany impact financial performance. Despite these hurdles, the company increased its forecast for core EBITDA margins to 23%-23.5% for 2026.
Why it matters
The revised outlook reflects short-term operational challenges, specifically biosimilar-supply constraints, that have necessitated a recalibration of short-term financial expectations. This adjustment highlights the ongoing sensitivity of the firm's growth targets to global manufacturing and market factors.
Sandoz reported $2.94 billion in net sales for the third quarter, with the biosimilars unit contributing $998 million, reflecting a 17% increase at constant exchange rates. The company now expects annual net sales growth of 5-6%.
The players
Sandoz
Headquartered in Zurich, this pharmaceutical company specializes in the development and manufacturing of biosimilars and generic medicines.
The details
Supply chain issues and a challenging environment in Germany weighed on results, prompting the updated guidance despite recent regulatory approvals for diabetes and obesity drugs in Brazil and Canada. Sandoz continues to focus on long-term expansion, targeting a 100-drug biosimilars portfolio by 2040.
Timeline
March 2026: Sandoz filed an anti-dumping complaint regarding Chinese amoxicillin.
September 2026: The company held its capital markets day.
October 28, 2026: Sandoz officially updated its 2026 financial guidance.
2035: The target year for doubling annual net sales.
2040: The target year for reaching a 100-drug biosimilars portfolio.
Health Landscape
This financial update adjusts the short-term operational benchmarks for the Sandoz biosimilars expansion program. It highlights the internal pressures companies face when scaling large-scale generic portfolios while maintaining profit margins amid supply volatility.
Patients may see shifts in the availability of specific biosimilar treatments as the company manages supply constraints in various regions. Ongoing regulatory approvals for obesity and diabetes medications in markets like Brazil and Canada indicate a continued focus on expanding treatment options.
The takeaway
The company remains committed to its long-term strategy of scaling biosimilar production to reach 100 drugs by 2040. Investors and stakeholders should monitor how the firm navigates short-term supply chain pressures while attempting to double net sales by 2035.
Further reading
Learn more about the latest industry developments in Diabetes.
Live Poll
Do you trust pharmaceutical companies to handle supply constraints without compromising long-term financial stability?
